Journal
FRONTIERS IN IMMUNOLOGY
Volume 4, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2013.00152
Keywords
Treg cells; Treg stability; immunotherapy; Treg function; gene expression profiling; TCR repertoire
Categories
Funding
- National Institutes of Health [RO1 AI073731, RO1 AI085090]
- Crohn's and Colitis Foundation of America [2858]
- D.B. and Marjorie Reinhart Family Foundation
- Children's Hospital of Wisconsin
- NIGMS [GM080202]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073731, R01AI085090] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080202] Funding Source: NIH RePORTER
Ask authors/readers for more resources
CD4(+) CD25(+) Foxp3(+) regulatory T (Treg) cells are essential to the balance between pro- and anti-inflammatory responses. There are two major subsets of Treg cells, natural Treg (nTreg) cells that develop in the thymus, and induced Treg (iTreg) cells that arise in the periphery from CD4(+) Foxp3(-) conventional T cells and can be generated in vitro. Previous work has established that both subsets are required for immunological tolerance. Additionally, in vitro-derived iTreg cells can reestablish tolerance in situations where Treg cells are decreased or defective. This review will focus on iTreg cells, drawing comparisons to nTreg cells when possible. We discuss the molecular mechanisms of iTreg cell induction, both in vivo and in vitro, review the Foxp3-dependent and -independent transcriptional landscape of iTreg cells, and examine the proposed suppressive mechanisms utilized by each Treg cell subset. We also compare the T cell receptor repertoire of the Treg cell subsets, discuss inflammatory conditions where iTreg cells are generated or have been used for treatment, and address the issue of iTreg cell stability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available